Topline results from a phase 2 study demonstrated that Allegro Ophthalmics’ first-in-class anti-integrin candidate, Luminate, can help restore vision in diabetic macular edema (DME) patients being treated with anti-VEGF therapy. The drug may also help those with chronic disease who no longer respond to anti-VEGF treatment.
To read the article, please visit American Academy of Ophthalmology: “Novel Integrin Inhibitor May Improve Efficacy Of Anti-VEGF Treatment”
BOSTON — Treatments for diabetic retinopathy with new mechanisms of action and new options for age-related macular degeneration will be garnering attention here at the American Society of Retina Specialists (ASRS) 2017 Annual Meeting.
To read the article, please visit Medscape: “Progress in Diabetic Retinopathy in the Spotlight at ASRS”
Allegro Ophthalmics expects to deliver some positive news about its Phase II DEL MAR trial that is evaluating the safety and efficacy of Luminate as an adjunctive therapy with anti-VEGFs in patients with diabetic macular edema (DME). Could the news put the company in a position for an initial public offering?
To listen to the podcast, please visit OIS Podcast: “Allegro’s Poised to Deliver Positive News at ASRS; Could an IPO Be Next? We Ask Vicken Karageozian”
David S. Boyer, MD, provides an overview of the phase 2 DEL MAR study with ALG-1001 (Luminate, Allegro) in patients with diabetic macular edema. With stage 1 of the study previously presented, Dr. Boyer details the recent findings of stage 2, which evaluated the safety and efficacy of ALG-1001 with bevacizumab (Avastin, Genentech) pretreatment or ALG-1001 combined with bevacizumab.
To view the video, please visit Eyetube: “DEL MAR: Phase 2, Stage 2”
Agent shows novel mechanism of action, binding in the retina to stop angiogenesis.
Integrins have recently emerged as a treatment target in vitreoretinal diseases. Like VEGF, they are a part of the angiogenic cascade. Integrins are involved in cell-surface interactions that allow new endothelial cells to grow in the extracellular space. Without the expression of integrins, neovascularization would not occur. Integrin receptors cross-activate receptors for VEGF and for platelet-derived growth factor, demonstrating that these factors are closely interrelated in the angiogenesis pathway.
To read the article, please visit Retina Today: “Anti-Integrin Therapy in Treatment of DME”
BALTIMORE — Luminate® (ALG-1001) from Allegro Ophthalmics met both its primary and secondary endpoints in a phase 2 trial for the treatment of diabetic macular edema, Peter K. Kaiser, MD, said at the Association for Research in Vision and Ophthalmology meeting here. The integrin antagonist was injected monthly for 3 months and then patients were off treatment for 2 months, compared with five monthly injections of bevacizumab. The study showed Luminate® was non-inferior to the anti-VEGF treatment with fewer injections.
To view the video, please visit Ocular Surgery News: “VIDEO: Luminate® Study Shows Equivalence to anti-VEGF with Fewer Injections”
John A. Hovanesian, MD, FACS, focuses his blog on new technologies and innovations and how ophthalmic practices can best incorporate them to benefit patients
To read the article, please visit Ocular Surgery News: “BLOG: Still Much Progress Ahead in Retina”